Information Maintained by the Office of Code Revision Indiana Legislative Services Agency
 05/12/2008 06:39:03 PM EDT
IC 35-48-2
     Chapter 2. Classification of Drugs

IC 35-48-2-1
Considerations of board in determinations on substances; controlled substances advisory committee; exclusion of a nonnarcotic substance from schedule
     Sec. 1. (a) The board shall administer this article and may recommend to the general assembly the addition, deletion, or rescheduling of all substances listed in the schedules in sections 4, 6, 8, 10, and 12 of this chapter by submitting in an electronic format under IC 5-14-6 a report of such recommendations to the legislative council. In making a determination regarding a substance, the board shall consider the following:
        (1) The actual or relative potential for abuse.
        (2) The scientific evidence of its pharmacological effect, if known.
        (3) The state of current scientific knowledge regarding the substance.
        (4) The history and current pattern of abuse.
        (5) The scope, duration, and significance of abuse.
        (6) The risk to public health.
        (7) The potential of the substance to produce psychic or physiological dependence liability.
        (8) Whether the substance is an immediate precursor of a substance already controlled under this article.
    (b) After considering the factors enumerated in subsection (a), the board shall make findings and recommendations concerning the control of the substance if it finds the substance has a potential for abuse.
    (c) If the board finds that a substance is an immediate precursor, substances which are precursors of the controlled precursor shall not be subject to control solely because they are precursors of the controlled precursor.
    (d) If any substance is designated or rescheduled to a more restrictive schedule as a controlled substance under federal law and notice is given to the board, the board shall recommend similar control of the substance under this article in the board's report to the general assembly, unless the board objects to inclusion or rescheduling. In that case, the board shall publish the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall publish its findings.
    (e) If a substance is rescheduled to a less restrictive schedule or deleted as a controlled substance under federal law, the substance is rescheduled or deleted under this article. If the board objects to inclusion, rescheduling, or deletion of the substance, the board shall notify the chairman of the legislative council not more than thirty (30) days after the federal law is changed and the substance may not be rescheduled or deleted until the conclusion of the next complete session of the general assembly. The notice from the board to the

chairman of the legislative council must be published.
    (f) There is established a sixteen (16) member controlled substances advisory committee to serve as a consultative and advising body to the board in all matters relating to the classification, reclassification, addition to, or deletion from of all substances classified as controlled substances in schedules I to IV or substances not controlled or yet to come into being. In addition, the advisory committee shall conduct hearings and make recommendations to the board regarding revocations, suspensions, and restrictions of registrations as provided in IC 35-48-3-4. All hearings shall be conducted in accordance with IC 4-21.5-3. The advisory committee shall be made up of:
        (1) two (2) physicians licensed under IC 25-22.5, one (1) to be elected by the medical licensing board of Indiana from among its members and one (1) to be appointed by the governor;
        (2) two (2) pharmacists, one (1) to be elected by the state board of pharmacy from among its members and one (1) to be appointed by the governor;
        (3) two (2) dentists, one (1) to be elected by the state board of dentistry from among its members and one (1) to be appointed by the governor;
        (4) the state toxicologist or the designee of the state toxicologist;
        (5) two (2) veterinarians, one (1) to be elected by the state board of veterinary medical examiners from among its members and one (1) to be appointed by the governor;
        (6) one (1) podiatrist to be elected by the board of podiatric medicine from among its members;
        (7) one (1) advanced practice nurse with authority to prescribe legend drugs as provided by IC 25-23-1-19.5 who is:
            (A) elected by the state board of nursing from among the board's members; or
            (B) if a board member does not meet the requirements under IC 25-23-1-19.5 at the time of the vacancy on the advisory committee, appointed by the governor;
        (8) the superintendent of the state police department or the superintendent's designee;
        (9) three (3) members appointed by the governor who have demonstrated expertise concerning controlled substances; and
        (10) one (1) member appointed by the governor who is a psychiatrist with expertise in child and adolescent psychiatry.
    (g) All members of the advisory committee elected by a board shall serve a term of one (1) year and all members of the advisory committee appointed by the governor shall serve a term of four (4) years. Any elected or appointed member of the advisory committee, may be removed for cause by the authority electing or appointing the member. If a vacancy occurs on the advisory committee, the authority electing or appointing the vacating member shall elect or appoint a successor to serve the unexpired term of the vacating member. The board shall acquire the recommendations of the

advisory committee pursuant to administration over the controlled substances to be or not to be included in schedules I to V, especially in the implementation of scheduled substances changes as provided in subsection (d).
    (h) Authority to control under this section does not extend to distilled spirits, wine, or malt beverages, as those terms are defined or used in IC 7.1, or to tobacco.
    (i) The board shall exclude any nonnarcotic substance from a schedule if that substance may, under the Federal Food, Drug, and Cosmetic Act or state law, be sold over the counter without a prescription.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977, P.L.344, SEC.1; P.L.137-1985, SEC.17; P.L.200-1987, SEC.4; P.L.188-1989, SEC.4; P.L.33-1993, SEC.73; P.L.163-1994, SEC.2; P.L.177-1997, SEC.8; P.L.14-2000, SEC.77; P.L.107-2002, SEC.31; P.L.28-2004, SEC.178.

IC 35-48-2-1.1
Repealed
    (Repealed by P.L.2-1995, SEC.140.)

IC 35-48-2-1.5
Advisory committee; officers; meetings; rules; per diem; expenses
     Sec. 1.5. (a) The advisory committee shall annually elect a chairperson and any other officers that the advisory committee determines necessary from among its members.
    (b) Meetings of the advisory committee may be called by:
        (1) the advisory committee chairperson; or
        (2) a majority of the members of the advisory committee.
    (c) Seven (7) members of the committee constitute a quorum.
    (d) Notwithstanding IC 1-1-4-1, if at least a quorum of its members are present at a meeting, the committee may take an action by an affirmative vote of at least a majority of the members present and voting.
    (e) The advisory committee shall adopt rules under IC 4-22-2 to:
        (1) set standards related to the registration and control of the manufacture, distribution, and dispensing of controlled substances, including record keeping requirements;
        (2) set fees described in IC 25-1-8; and
        (3) carry out its responsibilities under IC 35-48-2 through IC 35-48-3.
    (f) The Indiana professional licensing agency shall provide staff and facilities to the advisory committee under IC 25-1-5.
    (g) Each member of the committee who is not a state employee is entitled to the minimum salary per diem provided by IC 4-10-11-2.1(b). Such a member is also entitled to reimbursement for traveling expenses and other expenses actually incurred in connection with the member's duties, as provided in the state travel policies and procedures established by the department of administration and approved by the budget agency.

    (h) Each member of the committee who is a state employee is entitled to reimbursement for traveling expenses and other expenses actually incurred in connection with the member's duties, as provided in the state travel policies and procedures established by the department of administration and approved by the budget agency.
As added by P.L.200-1987, SEC.5. Amended by P.L.1-2006, SEC.546.

IC 35-48-2-2
Nomenclature
     Sec. 2. Nomenclature. The controlled substances listed in the schedules in sections 4, 6, 8, 10 and 12 of this chapter are included by whatever official, common, usual, chemical, or trade name designated. The number placed in brackets after each substance is its federal Drug Enforcement Administration Controlled Substances Code Number which is to be used for identification purposes on certain certificates of registration.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1979, P.L.303, SEC.2.

IC 35-48-2-3
Schedule I tests
     Sec. 3. (a) The board shall recommend placement of a substance in schedule I under this chapter if it finds that the substance:
        (1) has high potential for abuse; and
        (2) has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.
    (b) The board may recommend placement of a substance in schedule I under this chapter if it finds that the substance is classified as a controlled substance in schedule I under federal law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987, SEC.6.

IC 35-48-2-4
Schedule I
     Sec. 4. (a) The controlled substances listed in this section are included in schedule I.
    (b) Opiates. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted by rule of the board or unless listed in another schedule, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
        Acetylmethadol (9601)
        Allylprodine (9602)
        Alphacetylmethadol (9603)
        Alphameprodine (9604)
        Alphamethadol (9605)
        Alphamethylfentanyl (9614)
        Benzethidine (9606)

        Betacetylmethadol (9607)
        Betameprodine (9608)
        Betamethadol (9609)
        Betaprodine (9611)
        Clonitazene (9612)
        Dextromoramide (9613)
        Diampromide (9615)
        Diethylthiambutene (9616)
        Difenoxin (9168)
        Dimenoxadol (9617)
        Dimepheptanol (9618)
        Dimethylthiambutene (9619)
        Dioxaphetyl butyrate (9621)
        Dipipanone (9622)
        Ethylmethylthiambutene (9623)
        Etonitazene (9624)
        Etoxeridine (9625)
        Furethidine (9626)
        Hydroxypethidine (9627)
        Ketobemidone (9628)
        Levomoramide (9629)
        Levophenacylmorphan (9631)
        3-Methylfentanyl [N-[3-methyl-1-(2-phenylethyl)-4-
        piperidyl]-N-phenyl-propanimide](9813)
        MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) (9961)
        Morpheridine (9632)
        Noracymethadol (9633)
        Norlevorphanol (9634)
        Normethadone (9635)
        Norpipanone (9636)
        Phenadoxone (9637)
        Phenampromide (9638)
        Phenomorphan (9647)
        Phenoperidine (9641)
        PEPAP [1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine] (9663)
        Piritramide (9642)
        Proheptazine (9643)
        Properidine (9644)
        Propiram (9649)
        Racemoramide (9645)
        Tilidine (9750)
        Trimeperidine (9646)
    (c) Opium derivatives. Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted by rule of the board or unless listed in another schedule, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
        Acetorphine (9319)
        Acetyldihydrocodeine (9051)
        Benzylmorphine (9052)
        Codeine methylbromide (9070)
        Codeine-N-Oxide (9053)
        Cyprenorphine (9054)
        Desomorphine (9055)
        Dihydromorphine (9145)
        Drotebanol (9335)
        Etorphine (except hydrochloride salt) (9056)
        Heroin (9200)
        Hydromorphinol (9301)
        Methyldesorphine (9302)
        Methyldihydromorphine (9304)
        Morphine methylbromide (9305)
        Morphine methylsulfonate (9306)
        Morphine-N-Oxide (9307)
        Myrophine (9308)
        Nicocodeine (9309)
        Nicomorphine (9312)
        Normorphine (9313)
        Pholcodine (9314)
        Thebacon (9315)
    (d) Hallucinogenic substances. Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic, psychedelic, or psychogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted by rule of the board or unless listed in another schedule, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
        (1) 4-Bromo-2, 5-Dimethoxyamphetamine (7391). Some trade or other names: 4-Bromo-2, 5-Dimethoxy-a-methylphenethylamine; 4-Bromo-2, 5-DMA.
        (2) 2, 5-Dimethoxyamphetamine (7396). Some trade or other names: 2, 5-Dimethoxy-a-methylphenethylamine; 2, 5-DMA.
        (3) 4-Methoxyamphetamine (7411). Some trade or other names: 4-Methoxy-a-methylphenethylamine; Paramethoxyamphetamine; PMA.
        (4) 5-methoxy-3, 4-methylenedioxy amphetamine (7401). Other Name: MMDA.
        (5) 4-methyl-2, 5-dimethoxyamphetamine (7395). Some trade and other names: 4-methyl-2, 5-dimethoxy-a-methylphenethylamine; DOM; and STP.
        (6) 3, 4-methylenedioxy amphetamine (7400). Other name: MDA.
        (7) 3, 4-methylenedioxymethamphetamine (MDMA) (7405).
        (8) 3, 4, 5-trimethoxy amphetamine (7390). Other name: TMA.
        (9) Bufotenine (7433). Some trade and other names: 3-(B-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminonethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N, N-dimethyltryptamine; mappine.
        (10) Dimethyltryptamine (7434). Some trade or other names: N, N-Diethyltryptamine; DET.
        (11) Diethyltryptamine (7435). Some trade or other names: DMT.
        (12) Ibogaine (7260). Some trade and other names: 7-Ethyl-6, 6b, 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-pyrido (1', 2': 1, 2, azepino 4, 5-b) indole; tabernanthe iboga.
        (13) Lysergic acid diethylamide (7315). Other name: LSD.
        (14) Marijuana (7360).
        (15) Mescaline (7381).
        (16) Parahexyl (7374). Some trade or other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-Tetrahydro-6, 6, 9-trimethyl-6H-dibenzo (b,d) pyran; Snyhexyl.
        (17) Peyote (7415), including:
            (A) all parts of the plant that are classified botanically as lophophora williamsii lemaire, whether growing or not;
            (B) the seeds thereof;
            (C) any extract from any part of the plant; and
            (D) every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or extracts.
        (18) N-ethyl-3-piperidyl benzilate (7482). Other name: DMZ.
        (19) N-methyl-3-piperidyl benzilate (7484). Other name: LBJ.
        (20) Psilocybin (7437).
        (21) Psilocyn (7438).
        (22) Tetrahydrocannabinols (7370), including synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. and synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as:
            (A) .1 cis or trans tetrahydrocannabinol, and their optical isomers;
            (B) .6 cis or trans tetrahydrocannabinol, and their optical isomers; and
            (C) .3,4 cis or trans tetrahydrocannabinol, and their optical isomers.
        Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions are covered. Other name: THC.
        (23) Ethylamine analog of phencyclidine (7455). Some trade or other names: N-Ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl) ethylamine; cyclohexamine; PCE.
        (24) Pyrrolidine analog of phencyclidine (7458). Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; PHP.
        (25) Thiophene analog of phencyclidine (7470). Some trade or other names: 1-(1-(2-thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine; TPCP.
    (e) Depressants. Unless specifically excepted in a rule adopted by the board or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of

the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
        Gamma-hydroxybutyric acid (other names include GHB; gamma-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate) (2010)
        Mecloqualone (2572)
        Methaqualone (2565)
    (f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
        Fenethylline (1503)
        N-ethylamphetamine (1475)
        Methcathinone (1237) (Some other trade names: 2-Methylamino-1-Phenylpropan-I-one; Ephedrone; Monomethylpropion; UR 1431.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1979, P.L.303, SEC.3; Acts 1981, P.L.170, SEC.2; P.L.333-1983, SEC.1; P.L.327-1985, SEC.1; P.L.156-1986, SEC.4; P.L.200-1987, SEC.7; P.L.163-1994, SEC.3; P.L.2-1996, SEC.286; P.L.288-2001, SEC.15.

IC 35-48-2-5
Schedule II tests
     Sec. 5. (a) The board shall recommend placement of a substance in schedule II under this chapter if it finds that:
        (1) the substance has high potential for abuse;
        (2) the substance has currently accepted medical use in treatment in the United States, or currently accepted medical use with severe restrictions; and
        (3) the abuse of the substance may lead to severe psychological or physical dependence.
    (b) The board may recommend placement of a substance in schedule II under this chapter if it finds that the substance is classified as a controlled substance in schedule II under federal law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987, SEC.8.

IC 35-48-2-6
Schedule II
     Sec. 6. (a) The controlled substances listed in this section are included in schedule II.
    (b) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:
        (1) Opium and opiate, and any salt, compound, derivative, or

preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, naloxone, naltrexone, and their respective salts but including:
            (A) raw opium (9600);
            (B) opium extracts (9610);
            (C) opium fluid extracts (9620);
            (D) powdered opium (9639);
            (E) granulated opium (9640);
            (F) tincture of opium (9630);
            (G) codeine (9050);
            (H) ethylmorphine (9190);
            (I) etorphine hydrochloride (9059);
            (J) hydrocodone (9193);
            (K) hydromorphone (9150);
            (L) metopon (9260);
            (M) morphine (9300);
            (N) oxycodone (9143);
            (O) oxymorphone (9652); and
            (P) thebaine (9333).
        (2) Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in subdivision (b)(1) of this section, but not including the isoquinoline alkaloids of opium.
        (3) Opium poppy and poppy straw.
        (4) Cocaine (9041).
        (5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy) (9670).
    (c) Opiates. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
        Alfentanil (9737)
        Alphaprodine (9010)
        Anileridine (9020)
        Bezitramide (9800)
        Bulk dextropropoxyphene (nondosage forms) (9273)
        Dihydrocodeine (9120)
        Diphenoxylate (9170)
        Fentanyl (9801)
        Isomethadone (9226)
        Levomethorphan (9210)
        Levorphanol (9220)
        Metazocine (9240)
        Methadone (9250)
        Methadone-Intermediate, 4-cyano-2-dimethyl-amino-4, 4-diphenyl butane (9254)
        Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane- carboxylic acid (9802)
        Pethidine (Meperidine) (9230)

        Pethidine-Intermediate- A, 4-cyano-1-methyl-4-phenylpiperidine (9232)
        Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate (9233)
        Pethidine-Intermediate-C,1-methyl-4-phenylpiperidine-4-carb oxylic acid (9234)
        Phenazodine (9715)
        Piminodine (9730)
        Racemethorphan (9732)
        Racemorphan (9733)
        Sufentanil (9740)
    (d) Stimulants. Any material compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:
        (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers (1100).
        (2) Methamphetamine, including its salts, isomers, and salts of its isomers (1105).
        (3) Phenmetrazine and its salts (1631).
        (4) Methylphenidate (1724).
    (e) Depressants. Unless specifically excepted by rule of the board or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
        Amobarbital (2125)
        Gamma hydroxybutyrate
        Pentobarbital (2270)
        Phencyclidine (7471)
        Secobarbital (2315)
    (f) Immediate precursors. Unless specifically excepted by rule of the board or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:
        (1) Immediate precursor to amphetamine and methamphetamine: Phenylacetone (8501). Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone.
        (2) Immediate precursors to phencyclidine (PCP):
            (A) 1-phenylcyclohexylamine (7460); or
            (B) 1-piperidinocyclohexanecarbonitrile (PCC) (8603).
    (g) Hallucinogenic substances:
        Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product (7369).
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1979, P.L.303, SEC.4; Acts 1981, P.L.170, SEC.3; P.L.333-1983, SEC.2;

P.L.77-1984, SEC.13; P.L.327-1985, SEC.2; P.L.156-1986, SEC.5; P.L.329-1987, SEC.1; P.L.31-1998, SEC.9.

IC 35-48-2-7
Schedule III tests
     Sec. 7. (a) The board shall recommend placement of a substance in schedule III under this chapter if it finds that:
        (1) the substance has a potential for abuse less than the substances listed in schedule I and II under this chapter;
        (2) the substance has currently accepted medical use in treatment in the United States; and
        (3) abuse of the substance may lead to moderate or low physical dependence or high psychological dependence.
    (b) The board may recommend placement of a substance in schedule III under this chapter if it finds that the substance is classified as a controlled substance in schedule III under federal law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987, SEC.9.

IC 35-48-2-8
Schedule III
     Sec. 8. (a) The controlled substances listed in this section are included in schedule III.
    (b) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
        (1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in schedule II which compounds, mixtures, or preparations were listed on April 1, 1986, as excepted compounds under 21 CFR 1308.32, and any other drug of the quantitative composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances (1405).
        (2) Benzphetamine (1228).
        (3) Chlorphentermine (1645).
        (4) Clortermine (1647).
        (5) Phendimetrazine (1615).
    (c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
        (1) Any compound, mixture, or preparation containing:
            (A) amobarbital (2125);
            (B) secobarbital (2315);
            (C) pentobarbital (2270); or
            (D) any of their salts;

        and one (1) or more other active medicinal ingredients which are not listed in any schedule.
        (2) Any suppository dosage form containing:
            (A) amobarbital (2125);
            (B) secobarbital (2315);
            (C) pentobarbital (2270); or
            (D) any of their salts;
        and approved by the Food and Drug Administration for marketing only as a suppository.
        (3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt thereof (2100).
        (4) Chlorhexadol (2510).
        (5) Glutethimide (2550).
        (6) Lysergic acid (7300).
        (7) Lysergic acid amide (7310).
        (8) Methyprylon (2575).
        (9) Sulfondiethylmethane (2600).
        (10) Sulfonethylmethane (2605).
        (11) Sulfonmethane (2610).
        (12) A combination product containing tiletimine and zolazepam (Telazol) (7295).
        (13) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal Food, Drug and Cosmetic Act, 21 U.S.C. 301 et seq. (2012).
    (d) Nalorphine (a narcotic drug) (9400).
    (e) Narcotic Drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in the following limited quantities:
        (1) Not more than 1.8 grams of codeine, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium (9803).
        (2) Not more than 1.8 grams of codeine, per 100 milliliters or not more than 90 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts (9804).
        (3) Not more than 300 milligrams of dihydrocodeinone, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium (9805).
        (4) Not more than 300 milligrams of dihydrocodeinone, per 100 milliliters or not more than 15 milligrams per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts (9806).
        (5) Not more than 1.8 grams of dihydrocodeine, per 100 milliliters or not more than 90 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts (9807).
        (6) Not more than 300 milligrams of ethylmorphine, per 100 milliliters or not more than 15 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts (9808).
        (7) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts (9809).
        (8) Not more than 50 milligrams of morphine, per 100 milliliters or per 100 grams with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts (9810).
    (f) Anabolic steroid (as defined in 21 U.S.C. 802(41)(A) and 21 U.S.C. 802(41)(B)).
    (g) The board shall except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in subsections (b) through (e) from the application of any part of this article if the compound, mixture, or preparation contains one (1) or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.
    (h) Any material, compound, mixture, or preparation which contains any quantity of Ketamine.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977, P.L.2, SEC.86; Acts 1979, P.L.303, SEC.5; Acts 1981, P.L.170, SEC.4; P.L.333-1983, SEC.3; P.L.200-1987, SEC.10; P.L.48-1991, SEC.76; P.L.1-1994, SEC.171; P.L.31-1998, SEC.10; P.L.288-2001, SEC.16.

IC 35-48-2-9
Schedule IV tests
     Sec. 9. (a) The board shall recommend placement of a substance in schedule IV under this chapter if it finds that:
        (1) the substance has a low potential for abuse relative to substances in schedule III under this chapter;
        (2) the substance has currently accepted medical use in treatment in the United States; and
        (3) abuse of the substance may lead to limited physical dependence or psychological dependence relative to the substances in schedule III under this chapter.
    (b) The board may recommend placement of a substance in schedule IV under this chapter if it finds that the substance is classified as a controlled substance in schedule IV under federal law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987, SEC.11.

IC 35-48-2-10

Schedule IV
     Sec. 10. (a) The controlled substances listed in this section are included in schedule IV.
    (b) Narcotic drugs. Unless specifically excepted in a rule adopted by the board or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in the following limited quantities:
        (1) Not more than 1 milligram of difenoxin (9618) and not less than 25 micrograms of atropine sulfate per dosage unit.
        (2) Dextropropoxyphene (alpha- (+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybut ane (9273).
    (c) Depressants. Unless specifically excepted in a rule adopted by the board or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
        Alprazolam (2882).
        Barbital (2145).
        Bromazepam (2748).
        Camazepam (2749).
        Carisoprodol.
        Chloral betaine (2460).
        Chloral hydrate (2465).
        Chlordiazepoxide (2744).
        Clobazam (2751).
        Clonazepam (2737).
        Clorazepate (2768).
        Clotiazepam (2752).
        Cloxazolam (2753).
        Delorazepam (2754).
        Diazepam (2765).
        Estazolam (2756).
        Ethchlorvynol (2540).
        Ethinamate (2545).
        Ethyl loflazepate (2758).
        Fludiazepam (2759).
        Flunitrazepam (2763).
        Flurazepam (2767).
        Halazepam (2762).
        Haloxazolam (2771).
        Ketazolam (2772).
        Loprazolam (2773).
        Lorazepam (2885).
        Lormetazepam (2774).
        Mebutamate (2800).
        Medazepam (2836).
        Meprobamate (2820).
        Methohexital (2264).
        Methylphenobarbital (mephobarbital) (2250).
        Midazolam (2884).
        Nimetazepam (2837).
        Nitrazepam (2834).
        Nordiazepam (2838).
        Oxazepam (2835).
        Oxazolam (2839).
        Paraldehyde (2585).
        Petrichloral (2591).
        Phenobarbital (2285).
        Pinazepam (2883).
        Prazepam (2764).
        Quazepam (2881).
        Temazepam (2925).
        Tetrazepam (2886).
        Triazolam (2887).
        Zolpidem (Ambien) (2783).
    (d) Fenfluramine. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible.
        Fenfluramine (1670).
    (e) Stimulants. Unless specifically excepted in a rule adopted by the board or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
        (1) Diethylpropion (1608).
        (2) Mazindol (1605).
        (3) Phentermine (1640).
        (4) Pemoline (including organometallic complexes and chelates thereof) (1530).
        (5) Pipradrol (1750).
        (6) SPA ((-)-1-dimethylamino-1,2-diphenylethane (1635).
    (f) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances including its salts:
        (1) Pentazocine (9709).
    (g) The board may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection (b), (c), (d), (e), or (f) from the application of any part of this article if the compound, mixture, or preparation contains one (1) or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in

combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1977, P.L.344, SEC.2; Acts 1979, P.L.303, SEC.6; Acts 1981, P.L.170, SEC.5; P.L.333-1983, SEC.4; P.L.77-1984, SEC.14; P.L.200-1987, SEC.12; P.L.288-2001, SEC.17; P.L.8-2004, SEC.3.

IC 35-48-2-11
Schedule V tests
     Sec. 11. (a) The board shall recommend placement of a substance in schedule V under this chapter if it finds that:
        (1) the substance has low potential for abuse relative to the controlled substances listed in schedule IV under this chapter;
        (2) the substance has currently accepted medical use in treatment in the United States; and
        (3) the substance has limited physical dependence or psychological dependence liability relative to the controlled substances listed in schedule IV under this chapter.
    (b) The board may recommend placement of a substance in schedule V under this chapter if it finds that the substance is classified as a controlled substance in schedule V under federal law.
As added by Acts 1976, P.L.148, SEC.7. Amended by P.L.200-1987, SEC.13.

IC 35-48-2-12
Schedule V
     Sec. 12. (a) The controlled substances listed in this section are included in schedule V.
    (b) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in the following quantities, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than those possessed by the narcotic drug alone:
        (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
        (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
        (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
        (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
        (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
        (6) Not more than 0.5 milligrams of difenoxin (9168), and not less than 25 micrograms of atropine sulfate per dosage unit.
    (c) Buprenorphine (9064).

As added by Acts 1976, P.L.148, SEC.7. Amended by Acts 1979, P.L.303, SEC.7; Acts 1981, P.L.170, SEC.6; P.L.327-1985, SEC.3.

IC 35-48-2-13
Repealed
     (Repealed by Acts 1979, P.L.303, SEC.13.)

IC 35-48-2-14
Reclassification; rules
     Sec. 14. (a) The board may adopt rules under IC 4-22-2 to reclassify a controlled substance:
        (1) from a more restrictive schedule to a less restrictive schedule; or
        (2) as a substance that is not a controlled substance;
if the board finds that the substance qualifies for reclassification under this chapter and that the same reclassification has been made in a controlled substance schedule under federal law.
    (b) If the board reclassifies a controlled substance under subsection (a), the board shall recommend the same reclassification to the general assembly under section 1 of this chapter.
    (c) Notwithstanding a provision in this chapter that classifies a controlled substance in a more restrictive schedule than a rule adopted under subsection (a), a person who manufactures, distributes, dispenses, possesses, or uses a controlled substance in compliance with the requirements applicable to the less restrictive schedule to which a controlled substance is reclassified under subsection (a) does not commit an offense under this article.
    (d) Notwithstanding a provision in this chapter that classifies a substance as a controlled substance, a person does not commit an offense under this article if the board has reclassified the controlled substance as a substance that is not a controlled substance.
As added by P.L.200-1987, SEC.14.

accessIndiana

Agency Listing INShape Indiana Policies Contact Webmaster Help Go